Dorjee Shola

Dorjee Shola currently serves as Senior Scientist II at Prime Medicine, Inc. and has been in this role since July 2024. Additionally, Dorjee holds a position as Senior Scientist II in Gene Correction at ReCode Therapeutics since July 2022. Previous experience includes serving as Senior Scientist in Genetic Engineering at Poseida Therapeutics, Inc. from February 2021 to June 2022, and as Manager of Genome Editing at The Rockefeller University from November 2011 to January 2021, where leadership included overseeing the CRISPR & Genome Editing Resource Center. Educational qualifications feature a PhD in Molecular Biology from Case Western Reserve University and postdoctoral training in Genome Editing from The Rockefeller University. Prior academic endeavors include graduate studies in Molecular Parasitology at National Yang Ming University.